Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
Journal
JAMA dermatology
Journal Volume
158
Journal Issue
4
Pages
404
Date Issued
2022
Author(s)
Abstract
Primary results from the Measure Up 1 and Measure Up 2 studies demonstrated upadacitinib efficacy and safety through 16 weeks in patients with atopic dermatitis. Longer-term outcomes remain unknown.
Subjects
PLACEBO
SDGs
Publisher
AMER MEDICAL ASSOC
Type
journal article